Current status of COVID-19 treatment: An opinion review.
Antiviral drugs
COVID-19
Coronavirus
Eculizumab
Enoxaparin
Hydroxychloroquine
Opinion review
Pandemic
SARS-CoV-2
Tocilizumab
Treatment
Journal
World journal of virology
ISSN: 2220-3249
Titre abrégé: World J Virol
Pays: United States
ID NLM: 101608353
Informations de publication
Date de publication:
25 Sep 2020
25 Sep 2020
Historique:
received:
07
05
2020
revised:
07
08
2020
accepted:
24
08
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
ppublish
Résumé
The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has garnered the attention of scientists worldwide in the search for an effective treatment while also focusing on vaccine development. Several drugs have been used for the management of coronavirus disease 2019 (COVID-19), which has affected many hospitals and health centers worldwide. Statistically significant results are lacking on the effectiveness of the experimented drugs in reducing COVID-19 morbidity or mortality, as there are very few published randomized clinical trials. Despite this, the literature offers some material for study and reflection. This opinion review attempts to address three burning questions on COVID-19 treatment options. (1) What kind of studies are currently published or ongoing in the treatment of patients with COVID-19? (2) What drugs are currently described in the literature as options of treatment for patients affected by the infection? And (3) Are there specific clinical manifestations related to COVID-19 that can be treated with a customized and targeted therapy? By answering these questions, we wish to create a summary of current COVID-19 treatments and the anti-COVID-19 treatments proposed in the recent clinical trials developed in the last 3 mo, and to describe examples of clinical manifestations of the SARS-CoV-2 infection with a cause-related treatment.
Identifiants
pubmed: 33024717
doi: 10.5501/wjv.v9.i3.27
pmc: PMC7520874
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
27-37Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no conflict of interest.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Int J Antimicrob Agents. 2020 May;55(5):105938
pubmed: 32171740
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Antimicrob Agents Chemother. 2019 Sep 16;63(12):
pubmed: 31527024
J Thromb Haemost. 2020 Jul;18(7):1559-1561
pubmed: 32302453
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Sci Rep. 2020 Aug 4;10(1):13093
pubmed: 32753646
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Crit Care. 2015 Nov 27;19:418
pubmed: 26612352
Int J Environ Res Public Health. 2020 May 02;17(9):
pubmed: 32370204
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047
pubmed: 32329881
Lancet Respir Med. 2020 May;8(5):433-434
pubmed: 32203709
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Hellenic J Cardiol. 2020 Jan - Feb;61(1):42-45
pubmed: 32251729
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
J Chin Med Assoc. 2020 Jun;83(6):534-536
pubmed: 32243270
Dermatol Ther. 2020 Sep;33(5):e13475
pubmed: 32356577
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
Microb Pathog. 2020 Aug;145:104228
pubmed: 32344177
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
Autoimmun Rev. 2020 Jul;19(7):102566
pubmed: 32380315
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
JAMA. 2019 Oct 1;322(13):1261-1270
pubmed: 31573637
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Exp Cell Res. 2002 Nov 15;281(1):86-100
pubmed: 12441132
Pharmacol Res. 2020 Jul;157:104859
pubmed: 32360480
Travel Med Infect Dis. 2020 Mar - Apr;34:101615
pubmed: 32145386
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Isr Med Assoc J. 2020 Jun;22(6):335-339
pubmed: 32558435
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Med Virol. 2020 Nov;92(11):2693-2701
pubmed: 32497323